Analyzing the Target Gene Specificity of Tumor Suppressor AP2α
Author Information
Author(s): Kerschgens Jan, Renaud Stéphanie, Schütz Frédéric, Grasso Luigino, Egener-Kuhn Tanja, Delaloye Jean-François, Lehr Hans-Anton, Vogel Horst, Mermod Nicolas
Primary Institution: Institute of Biotechnology, University of Lausanne
Hypothesis
Can protein-binding microarrays (PBM) accurately identify the target genes of the tumor suppressor AP2α?
Conclusion
The study successfully identified novel target genes of AP2α involved in tumor progression and chemoresistance, demonstrating the effectiveness of PBM in clinical samples.
Supporting Evidence
- The PBM approach identified 282 DNA sequences significantly bound by AP2α.
- AP2α binding was confirmed in human carcinoma cells for novel target genes.
- AP2α target genes were associated with cancer and developmental processes.
- Binding values from PBM correlated well with surface plasmon resonance measurements.
- AP2α interactions were found to differ between normal and cancerous tissues.
Takeaway
Researchers used a special technique to find out which genes a protein called AP2α sticks to, helping us understand its role in cancer better.
Methodology
The study utilized protein-binding microarrays to assess AP2α binding to approximately 6000 human genomic DNA regulatory sequences.
Potential Biases
Potential biases may arise from the use of crude cellular extracts, which could affect the observed binding specificity of AP2α.
Limitations
The study's findings may not fully represent AP2α interactions in vivo due to the complexity of chromatin structure and other regulatory proteins.
Participant Demographics
The study involved nuclear extracts from 4 healthy breast tissues and 8 breast cancer biopsies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website